Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie E Ter Hark

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Affective Disorders|February 13, 2022
The Potential of Polygenic Risk Scores to Predict Antidepressant Treatment Response in Major Depression: A Systematic ReviewJulia J Meerman, Sophie E Ter Hark, Joost G E Janzing, et al.
Journal of Psychiatric Research|April 9, 2022
Biomarkers as predictors of treatment response to tricyclic antidepressants in major depressive disorder: A systematic reviewSophie E Ter Hark, Cornelis F Vos, Rob E Aarnoutse, et al.
Clinical Pharmacokinetics|May 25, 2025
Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard DosingCornelis F Vos, Marieke J H Coenen, Sophie E Ter Hark, et al.
Brain, Behavior, & Immunity - Health|August 23, 2021
Association of the neutrophil to lymphocyte ratio and white blood cell count with response to pharmacotherapy in unipolar psychotic depression: An exploratory analysisCornelis F Vos, Tom K Birkenhäger, Willem A Nolen, et al.
Journal of Clinical Psychopharmacology|November 6, 2023
The Relationship of Early Sleep Improvement With Response to Pharmacotherapy in Unipolar Psychotic DepressionCornelis F Vos, Tom K Birkenhäger, Willem A Nolen, et al.
Translational Psychiatry|March 2, 2024
A genetic risk score to predict treatment nonresponse in psychotic depressionSophie E Ter Hark, Marieke J H Coenen, Cornelis F Vos, et al.
JAMA Network Open|May 8, 2023
Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical TrialCornelis F Vos, Sophie E Ter Hark, Arnt F A Schellekens, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 6, 2025
Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: a trial-based economic evaluationSophie E Ter Hark, Wietske Kievit, Gerjon Hannink, et al.
Journal of Psychopharmacology (Oxford, England)|March 5, 2020
A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)Sophie E Ter Hark, Stéphane Jamain, Dick Schijven, et al.
BMC Psychiatry|October 2, 2021
Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the NetherlandsCornelis F Vos, Rob E Aarnoutse, Marijke J M Op de Coul, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Affective Disorders|February 13, 2022
The Potential of Polygenic Risk Scores to Predict Antidepressant Treatment Response in Major Depression: A Systematic ReviewJulia J Meerman, Sophie E Ter Hark, Joost G E Janzing, et al.
Journal of Psychiatric Research|April 9, 2022
Biomarkers as predictors of treatment response to tricyclic antidepressants in major depressive disorder: A systematic reviewSophie E Ter Hark, Cornelis F Vos, Rob E Aarnoutse, et al.
Clinical Pharmacokinetics|May 25, 2025
Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard DosingCornelis F Vos, Marieke J H Coenen, Sophie E Ter Hark, et al.
Brain, Behavior, & Immunity - Health|August 23, 2021
Association of the neutrophil to lymphocyte ratio and white blood cell count with response to pharmacotherapy in unipolar psychotic depression: An exploratory analysisCornelis F Vos, Tom K Birkenhäger, Willem A Nolen, et al.
Journal of Clinical Psychopharmacology|November 6, 2023
The Relationship of Early Sleep Improvement With Response to Pharmacotherapy in Unipolar Psychotic DepressionCornelis F Vos, Tom K Birkenhäger, Willem A Nolen, et al.
Translational Psychiatry|March 2, 2024
A genetic risk score to predict treatment nonresponse in psychotic depressionSophie E Ter Hark, Marieke J H Coenen, Cornelis F Vos, et al.
JAMA Network Open|May 8, 2023
Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical TrialCornelis F Vos, Sophie E Ter Hark, Arnt F A Schellekens, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 6, 2025
Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: a trial-based economic evaluationSophie E Ter Hark, Wietske Kievit, Gerjon Hannink, et al.
Journal of Psychopharmacology (Oxford, England)|March 5, 2020
A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)Sophie E Ter Hark, Stéphane Jamain, Dick Schijven, et al.
BMC Psychiatry|October 2, 2021
Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the NetherlandsCornelis F Vos, Rob E Aarnoutse, Marijke J M Op de Coul, et al.
Pageof 1